Short-Term Benefits of Smoking Cessation Improve Respiratory Function and Metabolism in Smokers

Pezzuto, Aldo; Ricci, Alberto; D'Ascanio, Michela; Moretta, Alba; Tonini, Giuseppe; Calabrò, Noemi; Minoia, Valeria; Pacini, Alessia; De Paolis, Giuliana; Chichi, Eleonora; Carico, Elisabetta; Tammaro, Antonella

doi:10.2147/copd.s423148

Cited by 24 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 31 , 32 Furthermore, Pezzuto et al indicate that even one month of short-term smoking cessation improved lung function and cholesterol levels, which corroborates our results of smokers exhibiting worse survival on respiratory or cardiovascular disease. 33 Furthermore, we revealed that nonsmokers with COPD demonstrated a lower risk of all-cause mortality than smokers without COPD. Smoking itself exhibits a significant impact on mortality, 34 thus, smokers without COPD had a higher risk than nonsmokers with COPD.…”

Section: Discussionmentioning

confidence: 88%

Impact of Smoking and Chronic Obstructive Pulmonary Disease on All-Cause, Respiratory, and Cardio-Cerebrovascular Mortality

Kang,

Kim,

Nam

et al. 2024

COPD

View full text Add to dashboard Cite

Introduction Mortality differences in chronic obstructive pulmonary disease (COPD) between nonsmokers and smokers remain unclear. We compared the risk of death associated with smoking and COPD on mortality. Methods The study included participants aged ≥40 years who visited pulmonary clinics and were categorised into COPD or non-COPD and smoker or nonsmoker on the basis of spirometry results and cigarette consumption. Mortality rates were compared between groups using statistical analysis for all-cause mortality, respiratory disease-related mortality, and cardiocerebrovascular disease-related mortality. Results Among 5811 participants, smokers with COPD had a higher risk of all-cause (adjusted hazard ratio (aHR), 1.69; 95% confidence interval (CI), 1.23–2.33) and respiratory disease-related mortality (aHR, 2.14; 95% CI, 1.20–3.79) than nonsmokers with COPD. Non-smokers with and without COPD had comparable risks of all-cause mortality (aHR, 1.39; 95% CI, 0.98–1.97) and respiratory disease-related mortality (aHR, 1.77; 95% CI, 0.85–3.68). However, nonsmokers with COPD had a higher risk of cardiocerebrovascular disease-related mortality than nonsmokers without COPD (aHR, 2.25; 95% CI, 1.15–4.40). Conclusion The study found that smokers with COPD had higher risks of all-cause mortality and respiratory disease-related mortality compared to nonsmokers with and without COPD. Meanwhile, nonsmokers with COPD showed comparable risks of all-cause and respiratory mortality but had a higher risk of cardiocerebrovascular disease-related mortality compared to nonsmokers without COPD.

show abstract

Section: Discussionmentioning

confidence: 88%

Impact of Smoking and Chronic Obstructive Pulmonary Disease on All-Cause, Respiratory, and Cardio-Cerebrovascular Mortality

Kang,

Kim,

Nam

et al. 2024

COPD

View full text Add to dashboard Cite

show abstract

“…A cohort study of 120 clients was conducted from April to December 2021 examining results of respiratory function and lipids following a smoking cessation program. 32 Study results showed a statistically significant decrease in TC (P < .001) and increase in HDL (P < .02) after only one month of cessation. Although these studies had small samples, these results are promising for improvement in lipid profiles soon after smoking cessation.…”

Section: Smoking Cessationmentioning

confidence: 86%

Hyperlipidemia Prevention and Management Utilizing Lifestyle Changes

Giles

2024

J Midwife Womens Health

View full text Add to dashboard Cite

Hyperlipidemia incidence is on the rise and lifestyle behavior change is the first‐line therapy. Left untreated, hyperlipidemia can result in cardiovascular disease leading to increased morbidity and mortality in persons worldwide. Evidence has demonstrated behavioral changes such as increased exercise, healthy nutrition, smoking cessation, alcohol abstinence, and other lifestyle modification interventions significantly decrease the incidence and severity of hyperlipidemia. The purpose of this article is to review the evidence of lifestyle interventions in preventing and managing hyperlipidemia and to suggest innovative ways to integrate those techniques into clinical practice. Recommendations on hyperlipidemia specific to pregnancy, polycystic ovary syndrome, and estrogen deficiency are also discussed.

show abstract

“…Additionally, the analysis did not take tobacco use into account, which can be an important factor in the pathophysiology of ILD. Therefore, tobacco cessation should always be recommended for these patients [28,29].…”

Section: Discussionmentioning

confidence: 99%

Osteopontin as a Biomarker in Interstitial Lung Diseases

Iturbe-Fernández,

Pulito-Cueto,

Mora-Cuesta

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Osteopontin (OPN) is a glycoprotein involved in Th1 and Th17 differentiation, and inflammation and tissue remodeling. OPN is a biomarker of disease activity in patients with autoimmune inflammatory conditions. This study aimed to assess the diagnostic and prognostic value of OPN in interstitial lung diseases (ILDs). Between May 2016 and October 2019, 344 patients with ILD were recruited at the Hospital Universitario Marqués de Valdecilla (Spain) and were prospectively followed-up. This study involved the determination of OPN serum levels by ELISA and OPN RNA expression quantified using qPCR. Six genetic polymorphisms in OPN (rs28357094, rs2853749, rs2853750, rs11728697, rs7695531, and rs1126616) were genotyped using TaqMan assays. OPN serum levels were also assessed in 140 healthy controls. OPN serum levels (median [interquartile range]) were significantly higher in ILD patients than in controls (1.05 [0.75–1.51] ng/mL versus 0.81 [0.65–0.98] ng/mL in healthy controls; p < 0.01). OPN serum levels were inversely correlated with the forced vital capacity. OPN serum levels were also higher in ILD patients who died or underwent lung transplantation when compared with the remaining ILD patients (1.15 [0.80–1.72] ng/mL versus 0.99 [0.66–1.32] ng/mL; p = 0.05). Survival worsened in ILD patients with OPN > 1.03 ng/mL at 1, 3, and 5 years. No statistically significant differences in the genetic frequencies of OPN polymorphisms or the RNA expression were found among the different ILD groups. Elevated levels of OPN in the serum may be a useful indicator in identifying patients with ILD who are more likely to experience poor outcomes.

show abstract

Short-Term Benefits of Smoking Cessation Improve Respiratory Function and Metabolism in Smokers

Cited by 24 publications

References 27 publications

Impact of Smoking and Chronic Obstructive Pulmonary Disease on All-Cause, Respiratory, and Cardio-Cerebrovascular Mortality

Impact of Smoking and Chronic Obstructive Pulmonary Disease on All-Cause, Respiratory, and Cardio-Cerebrovascular Mortality

Hyperlipidemia Prevention and Management Utilizing Lifestyle Changes

Osteopontin as a Biomarker in Interstitial Lung Diseases

Contact Info

Product

Resources

About